This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable...

This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable...

China’s National Medical Products Administration recently approved satricabtagene autoleucel (satri-cel, CARsgen), making it the world’s first chimeric antigen receptor (CAR) T-cell therapy approved f...

This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable...

A pioneering CAR-T cell therapy, satri-cel (CT041), is set to become available in China, marking the first time this advanced immunotherapy targets solid tumors, specifically advanced gastric and panc

Für Patienten mit fortgeschrittenem Magenkrebs nach zwei gescheiterten Therapielinien gab es bisher kaum noch Behandlungsoptionen. Das chinesische Biotech CARsgen hat das geändert: Satri-cel ist weltweit die erste CAR-T-Therapie, die je für einen sol

CARsgen Therapeutics has launched Satri-cel, the first CAR T-cell therapy approved for solid tumors. It targets advanced gastric cancer, offering new hope for patients.

CARsgen's novel Satri-cel therapy has demonstrated preliminary effectiveness in treating pancreatic cancer, as highlighted at ESMO Congress 2025.

Nature Biotechnology - First CAR T for solid tumors

A pioneering CAR-T cell therapy, satri-cel (CT041), designed specifically for solid tumors, is anticipated to become available in China in the first half of 2026. This therapy targets Claudin18.2, a b

This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable...

Jiahui International Cancer Center celebrates the approval of Satri-cel, marking a groundbreaking advancement in cancer treatment for solid tumors, available globally.

Jiahui International Cancer Center celebrates the approval of Satri-cel, a groundbreaking CAR-T cell therapy for solid tumors, offering hope to patients globally.

Jiahui International Cancer Center has announced the approval of Satri-cel, the world's first CAR-T cell therapy for solid tumors, bringing hope to patients globally.

/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as...

Китайский регулятор одобрил satri-cel для лечения распространенного рака желудка и рака гастроэзофагеального перехода. Препарат стал первой в мире CAR T терапией, разрешенной для применения против сол...

Jiahui International Cancer Center announces the approval of Satri-cel, a groundbreaking CAR-T therapy for solid tumors, providing hope for patients globally.

Trial in China is one of the first times the immune therapy has worked against solid tumours.

Discover the latest interim results from CARsgen Therapeutics as they highlight major advancements in CAR T-cell therapies and financial stability.

This edition highlights major developments across gene and cell therapy, including FDA approval of TREGZI, China's approval of satri-cel, progress toward the RGX-202 BLA submission, initiation of the Phase IIb/III NAAVIGATE study for sura-vec, expanded eligibility for CASGEVY, European approval of Itvisma for spinal muscular atrophy, a new Korean cell and gene therapy alliance led by GC Cell, and MeiraGTx's financing to support commercialization of late-stage gene therapy programs.

This biweekly Gene and Cell Therapy video recap highlights regulatory milestones, clinical progress, manufacturing collaborations, financing activity, and advancing development across multiple therapeutic areas. Key highlights include: 🧬 RGX-202 BLA path advances 👁️ Sura-vec NAAVIGATE begins 🧫 Satri-cel wins China approval 🩸 TREGZI gains FDA approval 👶 CASGEVY label expands to age 2+ 🧬 Itvisma wins EU SMA approval 🤝 GC Cell forms Korean CGT alliance 💰 MeiraGTx secures Oberland financing Chapters: 0:00 Introduction 0:09 RGX-202 BLA path advances 0:35 Sura-vec NAAVIGATE begins 0:58 Satri-cel wins China approval 1:18 TREGZI gains FDA approval 1:42 CASGEVY label expands to age 2+ 2:04 Itvisma wins EU SMA approval 2:24 GC Cell forms Korean CGT alliance 2:46 MeiraGTx secures Oberland financing 3:08 How to reach us 📢 Stay Ahead in Gene and Cell Therapy Research! ✅ Like, share, and subscribe for future updates on Gene and Cell Therapy ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Gene and Cell Therapy innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #GeneandCellTherapy #GeneTherapy #CellTherapy #FDA #ClinicalTrials #CART #RareDisease #Biotech #PharmaNews #LucidQuest